Phase 1 Study of Concurrent Sunitinib and Image-Guided Radiotherapy Followed by Maintenance Sunitinib for Patients With Oligometastases: Acute Toxicity and Preliminary Response

To determine the safety and maximum-tolerated dose of concurrent sunitinib and image-guided radiotherapy (IGRT) followed by maintenance sunitinib in oligometastastic patients. Eligible patients had 1 to 5 sites of metastatic cancer measuring

Saved in:
Bibliographic Details
Published in:Cancer 2009-08, Vol.115 (15), p.3571-3580
Main Authors: KAO, Johnny, PACKER, Stuart, HA LINH VU, SCHWARTZ, Myron E, SUNG, Max W, STOCK, Richard G, LO, Yeh-Chi, HUANG, Delphine, CHEN, Shu-Hsia, CESARETTI, Jamie A
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biological and medical sciences
Combined Modality Therapy - adverse effects
Disease-Free Survival
Female
Humans
Indoles - administration & dosage
Indoles - adverse effects
Male
Maximum Tolerated Dose
Medical sciences
Middle Aged
Neoplasm Metastasis - drug therapy
Neoplasm Metastasis - radiotherapy
Neoplasms - drug therapy
Neoplasms - pathology
Neoplasms - radiotherapy
Patient Compliance
Pyrroles - administration & dosage
Pyrroles - adverse effects
Radiation Dosage
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To determine the safety and maximum-tolerated dose of concurrent sunitinib and image-guided radiotherapy (IGRT) followed by maintenance sunitinib in oligometastastic patients. Eligible patients had 1 to 5 sites of metastatic cancer measuring
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.24412